Even though the emergency room doctors were eventually able to refer her to an internal medicine specialist, which in turn ...

Almost seven million people have a health condition that has forced them out of work or limited the amount they can do. As workers and businesses await government plans to grapple with the spiralling ...

Picture this: one tiny red bump from a summer hike. You slap on some cream, forget about it. Two years later, that same spot ...

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

The FDA approved the drug for Barth syndrome despite findings by its data reviewers that the treatment, while safe, was no ...

In the late 1960s, scientists discovered a miracle drug for Parkinson’s disease — a simple, inexpensive dopamine-replacement ...

UNC School of Medicine researchers have led an international clinical trial of patients with generalized myasthenia gravis, ...

Psychologists and technologists see them as the future of therapy. The Food and Drug Administration is exploring whether to ...

Nanobodies—tiny proteins derived from animals in the camelid family including camels, llamas, and alpacas—could be useful in ...

Eli Lilly and Co expects the U.S. Medicare health plan to back down from strict coverage limits on new Alzheimer's drugs as ...

Each year, about 100,000 Americans experience psychosis, a serious condition that disrupts thoughts and perceptions so profoundly that it can distort a person's sense of reality.

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.